Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
-
New drug combo tested for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called ERAS-601, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can shrink tum…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New drug cocktail aims to halt Hard-to-Treat skin cancer
Disease control OngoingThis study tests a new combination of two drugs, naporafenib and trametinib, in people with advanced NRAS-mutant melanoma that has already been treated. The goal is to see if this combo works better than standard treatments (dacarbazine, temozolomide, or trametinib alone) at slow…
Phase: PHASE3 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New drug duo targets hard-to-treat cancers with RAS mutation
Disease control OngoingThis early-stage study tests two drugs, naporafenib and trametinib, in people with advanced solid tumors that have a specific RAS Q61X gene mutation. The goal is to see if the combination can shrink tumors or slow their growth. About 86 participants aged 12 and older who have tri…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC